Sign in
Not yet taking people in CzechiaPhase 3

Tests semaglutide effects on liver fat in adults with obesity and fatty liver

Tests semaglutide for 16 weeks in adults with obesity and fatty liver disease.

Key facts

Who runs it
Institut Klinicke A Experimentalni Mediciny
Where
Prague 4, CzechiaSee the site
Registry title
The effect of semaglutide therapy on hepatic fat content and on the acute response of liver fat to high-fat load
Status
Not yet recruiting
Phase
Phase 3
People taking part
16 people, planned
Started
1 Jan 2026
Expected to end
31 Dec 2029
Type of study
Interventional
Record updated
28 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for men with obesity and fat in the liver. They would take semaglutide for 16 weeks.

Age
18 to 70 years
Sex
Men only
Disease stage
BMI of 30 kg/m2 or more, waist circumference of 102 cm (3 ft 4 in) or more, and liver fat above 5,5 % on an MRS scan at screening
Earlier treatment
No weight loss drugs; no long-term corticosteroids or immunosuppressants; no weight change of more than 5 % in the 3 months before the trial
Biomarker or test result
Liver fat content above 5,5 % measured by MRS during screening

Main reasons for not taking part

  • Type I or Type II diabetes
  • Active cancer or a past liver transplant
  • Alcohol use above 40 g/day
  • Active hepatitis, liver cirrhosis, or pancreatitis
  • Severe kidney failure or dialysis

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • sex: male
  • age 18 – 70 years
  • BMI ≥ 30 kg/m2
  • waist circumference ≥102 cm
  • hepatic fat content evaluated by MRS during screening > 5,5 %

Who cannot take part

  • chronic treatment with corticosteroids or immunosuppressants
  • significant change in weight (> 5 %) in the 3 months before the entering study
  • acute myocardial infarction, unstable angina pectoris, stroke, pulmonary embolism during 3 months before the start of study
  • diabetes mellitus Type I and Type II
  • active malignancy
  • history of liver transplantation or transplantation of insulin-producing tissue
  • any other disease that, in the opinion of investigator, could endanger or disadvantage the patient if he were to participate in the clinical trial
  • lactose intolerance, cow milk protein allergy or other intolerancies
  • hypersensitivity to the active substance or to any auxiliary substance of investigational medicinal product
  • heart failure NYHA IV
  • active hepatitis, liver cirrhosis
  • HbA1c ≥ 48 mmol/mol or fasting glycemia ≥ 7 mmol/l during screening
  • triglyceride > 4 mmol/l during screening
  • chronic renal insufficiency IV-V (eGFR ≤ 0,5 ml/s), end-stage renal failure, hemodialysis or peritoneal dialysis
  • alcohol consumption > 40 g/day
  • use of weight loss dugs
  • lack of legal capacity
  • refusal to sign informed consent
  • untreated thyreopathy
  • acute or chronic pancreatitis

Where in Czechia

  • Institut Klinicke A Experimentalni MedicinyPrague 4, CzechiaNot yet recruiting

About the trial

What the trial wants to find out

- to determine whether the treatment with semaglutide for 16 weeks favorably affects hepatic fat volume - to determine whether the treatment with semaglutide for 16 weeks favorably affects the acute response of hepatic fat content to a high-fat load

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
The effect of semaglutide therapy on hepatic fat content and on the acute reponse of liver fat to high-fat load in obese MASLD patients
Plain-language title
Tests semaglutide effects on liver fat in adults with obesity and fatty liverGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
28 May 2025